Cambrex Corp. (CBM) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cambrex Reports Third Quarter 2018 Financial Results
November 8, 2018 6:40 AM EST- Acquired Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base -
- Conference call at 8:30 a.m. ET on November 8, 2018 -
EAST RUTHERFORD, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, reports results for the third quarter ended September 30, 2018.
Third Quarter 2018 Highlights
Completed the acquisition of Halo Pharma (Halo), a leading finished dosage form Contract Development and... More